Intravitreal rituximab for the treatment of intraocular relapse of non-Hodgkin's lymphoma

Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria
Eva Fernández Cañabate, Sonia Fernández-Cañabate

Abstract

A 58-year-old woman with intraocular relapse of a diffuse large B cell lymphoma. Weekly intravitreal rituximab (1 mg/0.1 ml) for 4 weeks were  administered. 12 months after the last intravitreal rituximab dose, signs and  symptoms of lymphomas or adverse reactions associated with intravitreal Rituximab  administration were not observed. Intravitreal rituximab is an effective and safe treatment of intravitreal  lymphoma, by inducing complete remission; it could be a good alternative to other  therapeutic options with greater number of serious complications.

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.